KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income: 2018-2025

Historic Other Non Operating Income for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to $677,000.

  • Esperion Therapeutics' Other Non Operating Income fell 57.26% to $677,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $732,000, marking a year-over-year increase of 101.53%. This contributed to the annual value of -$54.9 million for FY2024, which is 1137.95% down from last year.
  • As of Q3 2025, Esperion Therapeutics' Other Non Operating Income stood at $677,000, which was up 1.65% from $666,000 recorded in Q2 2025.
  • Esperion Therapeutics' Other Non Operating Income's 5-year high stood at $3.9 million during Q4 2021, with a 5-year trough of -$53.2 million in Q2 2024.
  • In the last 3 years, Esperion Therapeutics' Other Non Operating Income had a median value of $1.1 million in 2023 and averaged -$3.9 million.
  • Its Other Non Operating Income has fluctuated over the past 5 years, first spiked by 16,312.50% in 2021, then crashed by 3,306.93% in 2024.
  • Over the past 5 years, Esperion Therapeutics' Other Non Operating Income (Quarterly) stood at $3.9 million in 2021, then slumped by 65.60% to $1.4 million in 2022, then declined by 20.30% to $1.1 million in 2023, then tumbled by 255.83% to -$1.7 million in 2024, then slumped by 57.26% to $677,000 in 2025.
  • Its last three reported values are $677,000 in Q3 2025, $666,000 for Q2 2025, and $1.1 million during Q1 2025.